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Abstract
Background: This study evaluates the surgical morbidity and long-term outcome of colorectal cancer surgery in an unselected
group of patients treated over the period 1994–2003.
Methods: A consecutive series of 902 primary colorectal cancer patients (489 M, 413 F; mean age: 63 years ± 11 years, range:
24–88 years) was evaluated and prospectively followed in a university hospital (mean follow-up 36 ± 24 months; range: 3–108
months). Perioperative mortality, morbidity, overall survival, curative resection rates, recurrence rates were analysed.
Results: Of the total, 476 colorectal cancers were localized to the colon (CC, 53%), 406 to the rectum (RC, 45%), 12 (1%) were
multicentric, and 8 were identified as part of HNPCC (1%). Combining all tumours, there were 186 cancers (20.6%) defined as
UICC stage I, 235 (26.1%) stage II, 270 (29.9%) stage III and 187 (20.6%) stage IV cases. Twenty-four (2.7%) cases were of
undetermined stage. Postoperative complications occurred in 38% of the total group (37.8% of CC cases, 37.2% of the RC group,
66.7% of the synchronous cancer patients and 50% of those with HNPCC, p = 0.19) Mortality rate was 0.8%, (1.3% for colon
cancer, 0% for rectal cancer; p = 0.023). Multivisceral resection was performed in 14.3% of cases. Disease-free survival in cases
resected for cure was 73% at 5-years and 72% at 8 years. The 5- and 8-year overall survival rates were 71% and 61% respectively
(total cases). At 5-year analysis, overall survival rates are 97% for stage I disease, 87% for stage II, 73% for stage III and 22% for
stage IV respectively (p < 0.0001). The 5-year overall survival rates showed a marked difference in R0, R1+R2 and non resected
patients (82%, 35% and 0% respectively, p < 0.0001). On multivariate analysis, resection for cure and stage at presentation but not
tumour site (colon vs. rectum) were independent variables for overall survival (p < 0.0001).
Conclusion: A prospective, uniform follow-up policy used in a single institution over the last decade provides evidence of quality
assurance in colorectal cancer surgery with high rates of resection for cure where only stage at presentation functions as an
independent variable for cancer-related outcome.
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Background
Although colorectal cancer (CRC) must be seen as a
tumour biological entity, the prognosis for colon cancer
and rectal cancer individually differs considerably. The
most important reason is certainly the great difference in
loco-regional tumour failure, which is significantly higher
for rectal cancer. In addition, adjuvant therapy regimens
for colon cancer and rectal cancer as well as neoadjuvant
radio/chemotherapy in selected patients with rectal cancer
differ substantially. Based on the International Union
Against Cancer (UICC)/American Joint Committee on
Cancer (AJCC) tumour staging system [1-5], complete
tumour removal (R0 resection) [1-7], is essential for local
tumour control and long term survival.
The aim of this study was to review a large consecutive
series of colorectal cancer patients prospectively followed
between 1994 and2003. Morbidity and long-term sur-
vival after colorectal cancer surgery in relation to stage and
radicality as well as after multivisceral resection, were ana-
lysed.
Methods
Patients
Between January 1994 and December 2003, a total of 902
patients were treated for primary colonic or rectal cancer.
Patients' median age was 63 ± 11 years (range 24–88
years). There were 489 men and 413 women. Tumours
were classified as rectal when adenocarcinomas were
located within 12 cm above the anal verge with rigid proc-
toscopy. Multicentric colorectal cancers were staged
according to the most advanced of the tumours.
Data concerning clinico-pathological staging and postop-
erative course were collected prospectively using a hospi-
tal tracking system based on ICD-coding for colorectal
cancer with all Histologically confirmed cases were
included. Eight hundred and seventy-three patients
(96.8%) underwent elective surgery after mechanical
bowel preparation using phosphates in 4 L of water, 29
patients (3.2%) were submitted to emergency surgery
without any bowel preparation. Among these there were
14 patients (1.6%) presenting with secondary large bowel
perforation, 12 (1.3%) with obstructing tumour and 3
(0.3%) with actively bleeding rectal cancer.
Preoperative staging
Preoperative staging was performed by abdominal ultra-
sound, thoraco-abdominal CT scan, abdominal magnetic
resonance imaging and endoscopic ultrasound as single
modalities or in combination depending on their availa-
bility and the surgeon's preference. All patients had at
least one form of preoperative imaging for staging pur-
poses.
Surgical procedure
Tumour resections were performed en bloc after ligation of
the segmental vessels, followed by lymph node dissection.
Anastomoses were established by stapling devices, usually
performed in an end-to-end fashion for left, transverse
and rectal resections and were termino-lateral for right
colon resections. In selected cases we performed anasto-
moses according to Knight-Griffen's technique [8]. Sta-
plers were routinely used. Coloanal anastomoses were
performed usually combined with a protective loop ileos-
tomy.
Standard resections were defined as tumour resections
including standard lymph dissections restricted to the
tumour-bearing bowel section. Multivisceral resections
were defined as "organs or structures adherent to the
tumour with a need for en bloc removal to obtain a cura-
tive situation". These multivisceral resections were classi-
fied according to the organ site (genitourinary system,
liver, small bowel) or as "various" (i.e.: abdominal wall,
large bowel). All operations were performed by the same
surgical team (BA, RB, AC, FL, SP, UP, EB); each of whom
had undergone postgraduate specialist training in colorec-
tal surgery.
Peroperative morbidity and mortality were registered fol-
lowing 30 days after surgery.
Pathology
Tumours were staged histopathologically and clinically
according to the TNM/Dukes/UICC system [9].
The radicality of the surgical procedure performed was
classified as "curative" (R0, no tumour left behind micro-
scopically at resection margins); "questionably curative"
(R1, tumour left behind microscopically at resection mar-
gins, or any other "Gray zone" situation that would ques-
tion a curative operation, such as suspect but unproven
metastases); "palliative" (R2, macroscopical tumour left
behind); or "unresectable" [4].
Adjuvant/neo-adjuvant treatments
Rectal cancer patients with locally advanced tumours (T3,
T4, or N positive) defined by preoperative staging investi-
gations, received bifractionated accelerated radiotherapy
for a maximum of 41.6 Gy or conventional radiotherapy
for a total of 50.4 Gy and concomitant chemotherapy
(within clinical studies with regimens containing 5-fluor-
ouracil, folinic acid, oxaliplatin, methotrexate or ralti-
trexed). Patients who did not receive neoadjuvant
therapies with a pathological staging pT3-4 N0 and pT1-
N1-2 cases received postoperative radio-chemotherapy.
For patients undergoing Mayo Clinic [10] or Machover
regimens [11] for 6 cycles "sandwich" schedules were used
(2 cycles CT→RT→4 cycles CT). Patients with a centralWorld Journal of Surgical Oncology 2007, 5:73 http://www.wjso.com/content/5/1/73
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venous system underwent continuous infusion chemo-
therapy with 5-FU concomitant with radiotherapy. The
treatment will last for 4–6 months. Chemotherapy regi-
mens as described were employed in an adjuvant setting
for patients who underwent preoperative bifractionated
radiotherapy or for C and D colon cancer patients. UICC
stage T3N0 colon cancer patients were candidate for the
same chemotherapy regimens according to the presence
of risk factors such as dedifferentiated tumour or vascular
invasion after counselling with medical oncologist.
The indication for additional treatment was assessed
either adjuvantly in curatively resected lesions in lymph
node-positive stages, or palliatively-resected cases for
stage IV or unresectable lesions. Liver or lung metastases
were resected if, an R0 situation was expected after resec-
tion. If in fact an R0 situation was obtained, these patients
were classified as R0 patients; otherwise they were R1 or
R2. Metastases were resected in 32 of 188 UICC stage IV
patients (17%) with synchronous liver metastses and
without additional metastatic spread. Of all 902 patients,
560 (62.1%) underwent additional treatment: chemo-
therapy in 438 (48.6%), radiotherapy in 4 (1%) and
radio-chemotherapy in 118 (13.1%) mainly for stage II or
III rectal cancer (111/122 patients, 91%, who underwent
postoperative radiotherapy). Eighty-four patients affected
by rectal cancer underwent neoadjuvant radiotherapy, in
36 of them (75%) associated with chemotherapy.
Follow-up
Patients were followed after curative resction using a fol-
low-up program. This program consisted of three appoint-
ments per year (years 1–3), two appointments per year
(years 4–5), and yearly appointments (years 6–10). All
appointments included clinical evaluation, carcinoem-
bryonic antigen (CEA) serum test, faecal blood test,
abdominal ultrasonography (months 8, 20, 30, 42, and
54), chest radiography (months 12, 24, 36, 48, and 60),
colonoscopy or double-contrast enema (months 12, 24,
48), rectal endoscopy (months 12, 24, 48), computed
tomography (CT) (months 4, 16, 30, 42, and 54), and
MRI where appropriate. When loco-regional recurrence
was suspected, positron emission tomography (PET)
scanning was used if available. Loco-regional recurrence
was defined as histologically- or radiologically-proven
disease presenting within the field of previous surgery.
Thirty-two patients (3.5%) were lost to follow-up. Mean
length of follow-up for 870 patients was 42 month (range
6–108).
Statistics
Analysis was performed using a statistical software pack-
age (SPSS, Chicago, IL advanced model statistical pack-
age). Comparison of variables was performed with the
Chi-square test and the Student's t-test for categorical and
continuous variables, respectively. Actuarial local recur-
rence and survival were analysed using the Kaplan-Meier
method with comparisons between groups being made
with the log-rank test. Multivariate analysis was per-
formed using the Cox proportional Hazard model where
p values < 0.05 were considered to be significant.
Results
Operative findings
A total of 902 patients with colorectal cancer were
included in the analysis. Among the lesions, 476 (53%)
were localized in the colon, 406 (45%) in the rectum, 12
(1%) were multicentric and 8 (1%) were identify as a part
of HNPCC. Surgical procedures are listed in Table 1.
Among these, there were 12 patients whose tumour was
excised transanally, 7 patients submitted to low anterior
resection or Miles operation who showed a complete
response to neoadjuvant RT-CT. Palliative treatment was
undertaken in 21.6% (196 of the patients), and consisted
mainly of tumour resection in patients with metastases.
The tumour was unresectable in 3% (27 of patients) in
Table 1: Type of surgical procedures performed in 902 patients affected by colorectal cancer
COLON N(%) RECTUM N(%) MULTICENTRIC N(%) HNPCC N(%)
Anterior resection of rectum - 304 - -
Right colectomy 201 (42.3) - - -
Left colectomy 167 (35.0) - - -
Segmental resection 79 (16.7) - - 6 (75.0)
Abdomino-perineal resection - 73 (18.0) - -
Subtotal colectomy 6 (1.2) - 11 (91.7) 2 (25.0)
Hartmann resection 8 (1.7) 6 (1.5) - -
Diversion colostomy 3 (0.6) 11 (2.7) - -
Transanal excision - 12 (2.9) - -
Colonic by-pass 10 (2.1) - - -
Explorative laparotomy 2 (0.4) - 1 (8.3) -
Total 476 (100) 406 (100) 12 (100) 8 (100)World Journal of Surgical Oncology 2007, 5:73 http://www.wjso.com/content/5/1/73
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whom colostomy or intestinal by-pass was the preferred
procedure. Among these, there were 5 patients affected by
unresectable colon cancer without distant metastases who
underwent diversion colostomy or intestinal by-pass Mul-
tivisceral resections were performed in 14.3% of the
patients (129/902). The single organ-sites mainly
involved in multivisceral resections were the genitouri-
nary system (9.4%), and the small bowel (0.9%).
Mean intraoperative blood loss was 300 ± 267 mL (range
100–2200 mL) and rectal cancer surgery was significantly
associated with increased intraoperative bleeding (212 ±
187 vs 376 ± 308 mean blood loss for colonic vs rectal
resections respectively; p = 0.02). Sixteen patients were
intraoperatively transfused (1.8%) with a mean of 1046 ±
867 mL of packed red blood cells (range 500–3000 mL).
Pathology
The stage distribution of the tumours treated is shown in
Table 2. Colon tumours were mainly UICC stages II, III or
IV (83.1%), and rectal tumours were of stages I, II or III
(86.2%). Tumour stage was not determined for 24 (2.7%)
of all tumours. The radicality of the surgical procedure is
shown in Table 3. The rate of R0 resections was 77.4% (n
= 699) for all patients, 73% (347/476) for colon cancer,
84.7% (344/406) for rectal cancer, and 66.7% (8/12) for
multicentric colorectal cancer (p < 0.0001). "Questiona-
bly curative" situations, including R1 resections or any
other situation that left doubt about the intended curative
character of the surgical procedure, occurred in 0.8% (7 of
all patients). In 107 out of 129 patients (82.9%) undergo-
ing multivisceral resection, an R0 situation was obtained.
Morbidity and mortality
Morbidity (Table 4) was documented in 38% of all
patients (343/902), 37.8% (180/476) of colon cancer
patients, 37.2% (151/406) of rectal cancer patients, 50%
(4/8) of HNPCC, and 66.7% (8/12) of multicentric color-
ectal cancer patients (p = 0.19). The mean intraoperative
blood loss for patients who developed or not postopera-
tive complications was 388 ± 384 vs 254 ± 164 respec-
tively (p = 0.018). The rates of anastomotic leakage were
7% in all 778 patients who had an anastomosis, 5.5%
(26/456) for colon patients, 10.4% (33/305) for rectum
patients, p = 0.01. Wound infections occurred in rectal
cancer patients with a frequency of 20% (81/406) and in
those with colon cancer in 19.3% (92/476). Complica-
tions were observed equally often in standard and multi-
visceral resections (37.5% vs. 41.1%, p = 0.44). Nineteen
patients required reoperation (13 for anastomotic leak-
age; 2 for small bowel obstruction; 3 for wound dehis-
cence, and 1 for mesenteric ischemia). Reoperation was
slightly more frequent after colonic (2.7%; 13/476) than
rectal resection (1.2%; 5/406) (p = 0.12), and after multi-
visceral than standard resection (3.1%; 4/129 vs. 1.9%;
15/773) (p = 0.4). The incidence of perioperative blood
transfusions was 10.9% (98 patients who received a mean
of 857 ± 792 mL of packed red blood cells) with no signif-
icant difference between colon and rectal cancer patients
(43/476, 9% for colon vs. 52/406, 12.8% for rectum; p =
0.072). Patients who underwent multivisceral resection
were more likely to be transfused (21/129, 16.3% vs. 77/
773, 10%; p = 0.03). The overall complication rate was
associated to perioperative blood transfusions (284/804
patients having complications, 35.3%, among non trans-
fused vs. 59/98, 60.2% among transfused patients; p <
0.0001).
The 30-day mortality rate was 0.8% (7/902) for all
patients. Mortality was 1.3% for colon cancer (6 patients),
and 0% for rectal cancer (p = 0.023). There was no differ-
ence in the mortality rate between standard and multivis-
ceral resections (0.6%, 5/773 vs. 1.6%, 2/129); p = 0.28).
Peroperative mortality rate was significantly correlated
with the radicality of the surgical procedure where 0.1%
mortality rate (1 patient) was noted for R0 resections,
2.8% (5 patients) for R1+R2 resections and 3.8% (1
patient) for unresected patients (p < 0.0001).
Tumour recurrence
Patterns of recurrence are represented in table 5. Distant
recurrence was the main focus of recurrence both in colon
and in rectal cancer. However, local recurrence was signif-
icantly more common in rectal cancer patients, associated
or not with distant recurrence in 6.1% (29/476) colon;
14.0%, (57/476) rectum (p < 000.1). The total rate of dis-
tant metastases into the liver or lungs were resected when-
ever possible; otherwise they were treated systematically
or regionally (liver).
Table 2: UICC tumour stage according to site of primary tumour. Mainly, there were more rectal cancers in UICC stage I and colon 
cancers in UICC stage IV (p < 0.0001).
UICC I UICC II UICC III UICC IV Undetermined Total
Colon cancer 80 (16.8) 131 (27.5) 130 (27.3) 132 (27.7) 3 (0.6) 476 (100)
Rectal cancer 97 (23.9) 99 (24.4) 136 (33.5) 53 (13.1) 21 (5.2) 406 (100)
HNPCC* 8  ( 1 0 0 ) 0000 8  ( 1 0 0 )
Multicentric 1 (8.3) 4 (33.3) 4 (33.3) 3 (25) 0 12 (100)
*HNPCC: hereditary non polyposis colorectal cancerWorld Journal of Surgical Oncology 2007, 5:73 http://www.wjso.com/content/5/1/73
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Disease-free survival rate for the 699 R0 patients was 73%
and 72% at 5 and 8 years respectively and was signifi-
cantly influenced by the site of the tumour where 5-year
disease-free survival rates for colon, rectum and multicen-
tric tumours were 78%, 68% and 24% respectively (p <
0.0001).
Overall survival rates
Five- and 8-years overall survival rates were 71% and 61%
respectively (total cases) and were significantly dependent
on tumour stage (Figure 1).
We decided to perform an univariate analysis on overall
survival assessing UICC tumour stage, tumour site (colon
vs. rectum vs. multicentric), sex, age (> or <65 years), adju-
vant or neoadjuvant treatments, radicality of surgery (R0
vs. R1 vs. R2), postoperative anastomotic leak, periopera-
tive blood transfusions.
For all patients, 5-year survival rates were 97% (UICC I),
87% (UICC II), 73% (UICC III), and 22% (UICC IV), dif-
fering significantly (p < 0.0001). The T, N, and M catego-
ries significantly influenced survival. Five-year survival
rates for T1, T2, T3 and T4 cases were respectively 96%,
87%, 73% and 45% (p < 0.0001). N0 significantly dif-
fered from any other N category, where 5-year survival
rates for N0, N1 and N2 patients were 86%, 67% and 43%
respectively (p < 0.0001) (log-rank test).
Overall 5-year survival rates for patients affected by colon,
rectal, or multicentric tumour were 69 vs. 73 vs. 63 respec-
tively (p = 0.061). Neither sex or age >65 year affected
overall survival (p = 0.72 and p = 0.12 respectively), nor
did the occurrence of an anastomotic leak, (p = 0.85).
For colon cancer (Figure 2a), the 5-year survival rates were
100% (UICC I), 91% (UICC II), 76% (UICC III), and
16% (UICC IV). In the group of UICC T3N0 colon-cancer
patients we registered a slight but not significant better
survival (92% vs. 80% at 5 years; p = 0.58) among those
who underwent adjuvant chemotherapy.
Rectal cancers (Figure 2b) showed 5-year survival rates of
93% (I), 83% (II), 68% (III), 36% (IV), with significant
differences (p < 0.0001). Rectal cancer patients undergo-
ing neoadjuvant radiotherapy had a similar overall sur-
vival in comparison to patients undergoing postoperative
radiotherapy (82% vs. 78% respectively; p = 0.13).
The 5-year overall survival showed a marked difference in
R0, R1+R2 resection patients and unresected patients with
a survival of 82%, 35% and 0% respectively, where a sig-
nificant difference was noted between R0 vs R1+R2 cases
(p < 0.0001) and R1+R2 vs. unresected cases (p = 0.0009)
(Figure 3). The influence of any subsequent adjuvant, first
line or palliative treatment was not analysed in detail and
consisted of heterogeneous groups.
Table 3: Surgical radicality according to site of primary tumour. Mainly, there were more rectal cancer patients undergoing R0 
resection than colon cancer patients (p < 0.0001).
R0 resection R1+R2 resection Non resected Total
Colon cancer 339 (71.2) 121 (25.4) 16 (3.4) 476 (100)
Rectal cancer 344 (84.7) 53 (13.1) 9 (2.2) 406 (100)
HNPCC* 8 (100) 0 0 8 (100)
Multicentric 8 (66.7) 3 (25) 1 (8.3) 12 (100)
*HNPCC: hereditary non polyposis colorectal cancer
Table 4: Complications following surgery according to site of primary tumour. Anastomotic dehiscence were more common after 
anterior resection of rectum than after surgery for colonic cancer.
Colon cancer Rectal cancer HNPCC* Multicentric p
Overall complications 180/476 (37.8) 151/406 (37.2) 4/8 (50) 8/12 (66.7) 0.19
Postoperative haemoperitoneum 3/476 (0.4) 2/406 (0.5) 0 0 0.98
Anastomotic dehiscence 26/456 (5.5) 33/305 (10.4) 2/8 (25) 0 0.01
Abdominal abscess 17/476 (3.6) 6/406 (1.5) 0 2/12 (16.7) 0.006
Wound complications 92/476 (19.3) 81/406 (20) 3/8 (37.5) 4/12 (37.6) 0.39
Pneumonia 16/476 (3.4) 4/406 (1) 0 4/12 (37.3) 0.025
Ileus 7/476 (1.5) 2/406 (0.5) 0 1/12 (8.3) 0.051
Urinary tract infection 8/476 (1.7) 15/406 (3.7) 0 1/12 (8.3) 0.16
CVC§infection 19/476 (4.0) 17/406 (4.2) 0 1/12 (8.3) 0.82
Cardiovascular 9/476 (1.9) 5/406 (1.2) 0 2/12 (16.7) 0.001
Others minor medical complications 8/476 (1.7) 8/406 (2.0) 0 0 0.92World Journal of Surgical Oncology 2007, 5:73 http://www.wjso.com/content/5/1/73
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Perioperative blood transfusions didn't influence overall
survival (71% and 63% at 5 and 8 years for transfused vs.
73% and 51% for transfused patients respectively; p =
0.68).
Multivariate analysis
Factors significant on univariate analysis were matched in
a multivariate analysis on overall survival assessing UICC
tumour stage, radicality of surgical procedure, and tumour
site, where only surgical radicality and UICC tumour stage
were associated with outcome (Table 6).
Discussion
The present study showed that a uniform policy of treat-
ment could provide exceptionally low postoperative mor-
tality rates (0.8%) and excellent results in terms of long-
term survival rate (71% at 5 years) in an unselected and
consecutive series of colorectal cancer patients who under-
Survival according to UICC tumour stage (7 patients who died peroperatively were excluded from the analysis) Figure 1
Survival according to UICC tumour stage (7 patients who died peroperatively were excluded from the analysis).
Table 5: Patterns of recurrence in 698 patients undergoing R0 resection for colorectal cancer according to site of primary tumour. 
Local recurrence were significantly more common in rectal cancer patients (p < 0.0001).
Local recurrence Local+distant recurrence Distant recurrence Total
Colon cancer 18 (5.2) 11 (3.2) 125 (36.1) 346 (100)
Rectal cancer 37 10.8 20 (5.8) 56 (16.3) 344(100)
Multicentric 2 (25) 1 (12.5) 4 (50) 8 (100)World Journal of Surgical Oncology 2007, 5:73 http://www.wjso.com/content/5/1/73
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went surgery. The ability to remove the primary tumour
also in presence of adjacent organ infiltration was one of
the main cause of success in our series.
Most colorectal cancers referred to surgical units can be
resected, as seen by our overall tumour-resection rate of
97%. This seems remarkable because the prognosis for
patients with unresectable tumours was even worse than
after palliative resection. However, the institutional resec-
tion rate is influenced by both the surgeon and patient fac-
tors and can therefore never be taken absolutely or be
regarded as a quality-control parameter.
The group of patients with synchronous multicentric
colorectal cancer (in our series 1%), is usually not referred
to in reports of colorectal-treatment outcome [12] ,
whereas metachronous colorectal cancer occurs in 0.5%
to 4.0% of cases [13,14]. The reported rate of synchronous
multicentric colorectal cancer is 2% to 10% and occurs in
older patients, mainly in the sigmoid loop and in 30% of
cases in nonadjacent colon segments [15]. Synchronous
colorectal cancers are usually classified according to site
with most advanced-stage tumour and do not show any
prognostic differences compared to single-site tumours.
However, their existence supports the need for complete
staging with total colonoscopy and biopsy of all suspected
lesions preoperatively. If total preoperatively colonoscopy
cannot be performed, it should be done not later than 3
months postoperatively. Whenever possible, endoscopic
polypectomy should be performed prior to surgery.
We registered a morbidity of 38%, and a mortality of 0,8%
during the past 9 years of CRC surgery. The apparently
high incidence of postoperative overall complication rate
may be due to the accurate monitoring and registration of
late complications as suggested by others [16]. Con-
versely, the perioperative mortality figure is quite low in
comparison to those reported in literature for elective
operations [17]. A possible explanation is that, as recently
demonstrated by Billingsley et al. [18] , very high surgeon
volumes are associated with a reduction in surgical com-
plications. However, the association between increasing
hospital volumes and postoperative mortality appears to
derive mainly from a full spectrum of clinical services that
may facilitate the prompt recognition and treatment of
complications. Our findings led us to conclude that
although increasing surgeon volumes may decrease com-
plications, decreasing complications is not the major
mechanism by which practice volumes decrease postoper-
ative mortality. In fact, minimizing postoperative mortal-
ity is associated primarily with systems that provide
increased safety in the postoperative period. Our reported
7% rate of anastomotic leakage (5,5% colon, 10,4%rec-
tum) is within the reported range [19]. We prefer stapled
(a) Survival according to UICC tumour stage for colon cancer patients undergoing surgery Figure 2
(a) Survival according to UICC tumour stage for colon cancer patients undergoing surgery. (b) Survival according to UICC 
tumour stage for rectal cancer patients undergoing surgery.World Journal of Surgical Oncology 2007, 5:73 http://www.wjso.com/content/5/1/73
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anastomoses. Some authors reported a strong relationship
between postoperative anastomotic leakage and long-
term survival [20]. These findings were not confirmed by
our study.
Long-term survival after resection of CRC depends on
tumour stage and radicality of the surgical procedure. We
observed overall 5-year survival rates of 82% (R0), 35%
(R1+R2), 0% (unresectable) in CRC patients. Others
reported similar results [19,21-24]. Therefore, the main
aim of any surgical procedure is to obtain an R0 resection
and to circumvent unresectability even if multivisceral
resections are necessary. Multivisceral resections were per-
formed in 14,3% of our patients. This slightly higher rate
compared to other reported rates [25-27], is explained by
the relatively high number of rectal cancer patients in our
Division. Survival rates similar to those for standard resec-
tions were observed with multivisceral resections, as in
other reports [27-29], so long as R0 resections resulted.
However, in contrast to others [30] , we have also seen an
indication for multivisceral primary tumour removal
when resectable hepatic metastases were found or in
patients who were suitable to undergo neoaadjuvant
chemotherapy. The prognosis of patients with resectable
liver metastases is potentially curative, we observed
response rate in 10 patients out of 27 who underwent
neoadjuvant chemotherapy for liver metastses from CRC
(unpublished data). In these selected patients we
observed a 5-year survival rate of 64% following hepatic
surgery.
Table 6: Multivariate analysis on overall survival for colorectal 
cancer patients undergoing surgery according to different 
variables.
Hazard ratio 95% I. C. § p
Surgical radicality* 3.000 2.247–4.007 <0.0001
UICC tumour stage 1.972 1.569–2.477 <0.0001
Tumour site# 0.851 0.637–1.137 0.274
§I. C.: confidence interval
*R0 vs R1+R2 vs unresected patients
#Colon vs rectum vs multicentric cancer
Survival according to radicality of surgery Figure 3
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Local tumour recurrence is significantly influenced by sur-
gical technique but occurred in only 2% of cases according
to our analysis. We found a significantly higher disease-
free survival rate for colon cancer patients than rectal can-
cer patients: this was probably due to the relatively higher
prevalence of local recurrence in the latter group. Despite
these findings, overall survival was not different between
the two subgroups of patients. Salvage abdominoperineal
resection for recurrence following low anterior resection
of the rectum was a feasible option with potentially cura-
tive results. In fact, if local recurrence is resectable, and is
found in combination with resectable single-organ
metastses (liver or lung) it should be treated by resection
if morbidity is acceptable. Since distant metastases and
local recurrence occur in 4,5% of CRC patients and relapse
can be prevented at least in part by radiotherapy, chemo-
therapy, or both, stage dependent adjuvant treatment has
been recommended [31-33]. Adjuvant therapy for CRC
increased the 5-year survival in randomized studies from
43% to 50% (without adjuvant therapy), to 63% to 70%
(with adjuvant therapy) [31,32,34-36]. In our series, adju-
vant treatment for T3N0 colon cancer patients failed to
show any advantages in term of long-term overall sur-
vival. In fact, indications for adjuvant treatment in stage II
colorectal cancer are somewhat little established [37]
Indications for adjuvant therapy are currently seen for
colon-cancer T independent if the patient is affected by N
positive locally advanced or M+ disease.
Overall survival did not differ in our series for rectal-can-
cer patients who underwent preoperative vs. postopera-
tive radiotherapy. In a recent review authors reported that
preoperative radiotherapy improves local recurrence,
overall mortality, but does not increase in sphincter spar-
ing procedure rates [38]. However, the benefit of preoper-
ative vs. postoperative radiotherapy remains unclear and
debated. Hopefully, randomised controlled trials, which
utilise these alternative clinical end points, will in future
determine the precise percentages of the effect of different
chemoradiation schedules on disease-free and overall sur-
vival for rectal cancer patients.
We found a correlation between perioperative blood
transfusions and postoperative complication. This was
probably due to the fact that patients transfused were at
risk for their poor general conditions rather than for an
independent effect of blood transfusion itself. We found
no relationship between perioperative blood transfusions
and long-term survival as reported by others [39].
The usefulness of postoperative surveillance programs has
not been clarified yet. It seems likely that early detection
of recurrence should improve patients' prognosis [40]. We
adopted a uniform policy of follow-up over time with a
growing use of PET scan over the last years when recur-
rence is suspected and the patient could benefit from rad-
ical resection of the recurrent disease. This is supported by
other studies recently published [41,42].
Conclusion
In conclusion, our study confirmed that surgery for color-
ectal cancer is safe (mortality <1%). The main goals
remain correct staging of tumour and R0 resection. Multi-
visceral resections result in morbidity and survival rates
comparable to those for standard resections and neoadju-
vant treatment in these cases may be necessary.
For patients with R0 resections, adjuvant treatment
should be applied on the basis of common recommenda-
tions [30] , in special clinical situations (advanced disease,
obstruction and/or perforation), and best of all in control-
led studies. Despite all the potential and above-men-
tioned drawbacks of a follow-up and documentation
system maintained for more than 10 years, we further
conclude from our data that it is a useful tool for surgical
quality control.
In addition, it provides a considerably valid institutional
basis on which new clinical trials can be planned that will
answer open questions about minimal-access-robotic
assisted surgery, neoadjuvant treatment, multimodal ther-
apy for colorectal cancer.
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